Skip to main content
Article
Optimization of percutaneous biopsy for diagnosis and pretreatment risk assessment of neuroblastoma
Pediatric Blood and Cancer
  • Richard E. Overman, C.S. Mott Children's Hospital
  • Tanvi T. Kartal, C.S. Mott Children's Hospital
  • Aaron J. Cunningham, Oregon Health & Science University
  • Elizabeth A. Fialkowski, Oregon Health & Science University
  • Bindi J. Naik-Mathuria, Baylor College of Medicine
  • Sanjeev A. Vasudevan, Baylor College of Medicine
  • Marcus M. Malek, University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh
  • Ranjeet Kalsi, University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh
  • Hau D. Le, American Family Children's Hospital
  • Linda Cherney Stafford, American Family Children's Hospital
  • Timothy B. Lautz, Northwestern University
  • Benjamin T. Many, Northwestern University
  • Rachel E. Jones, Northwestern University
  • Andreana Bütter, Western University
  • Jacob Davidson, Western University
  • Andrew Williams, Western University
  • Roshni Dasgupta, Cincinnati Children's Hospital Medical Center
  • Jana Lewis, Cincinnati Children's Hospital Medical Center
  • Misty Troutt, Cincinnati Children's Hospital Medical Center
  • Jennifer H. Aldrink, The Ohio State University College of Medicine
  • Sara A. Mansfield, The Ohio State University College of Medicine
  • Dave R. Lal, Children's Hospital of Wisconsin Wauwatosa
  • Jerry Xiao, Children's Hospital of Wisconsin Wauwatosa
  • Rebecka L. Meyers, The University of Utah
  • Scott S. Short, The University of Utah
  • Erika A. Newman, C.S. Mott Children's Hospital
Document Type
Article
Publication Date
5-1-2020
URL with Digital Object Identifier
10.1002/pbc.28153
Abstract

Background: Image-guided percutaneous core needle biopsy (PCNB) is increasingly utilized to diagnose solid tumors. The objective of this study is to determine whether PCNB is adequate for modern biologic characterization of neuroblastoma. Procedure: A multi-institutional retrospective study was performed by the Pediatric Surgical Oncology Research Collaborative on children with neuroblastoma at 12 institutions over a 3-year period. Data collected included demographics, clinical details, biopsy technique, complications, and adequacy of biopsies for cytogenetic markers utilized by the Children's Oncology Group for risk stratification. Results: A total of 243 children were identified with a diagnosis of neuroblastoma: 79 (32.5%) tumor excision at diagnosis, 94 (38.7%) open incisional biopsy (IB), and 70 (28.8%) PCNB. Compared to IB, there was no significant difference in ability to accurately obtain a primary diagnosis by PCNB (95.7% vs 98.9%, P =.314) or determine MYCN copy number (92.4% vs 97.8%, P =.111). The yield for loss of heterozygosity and tumor ploidy was lower with PCNB versus IB (56.1% vs 90.9%, P <.05; and 58.0% vs. 88.5%, P <.05). Complications did not differ between groups (2.9 % vs 3.3%, P = 1.000), though the PCNB group had fewer blood transfusions and lower opioid usage. Efficacy of PCNB was improved for loss of heterozygosity when a pediatric pathologist evaluated the fresh specimen for adequacy. Conclusions: PCNB is a less invasive alternative to open biopsy for primary diagnosis and MYCN oncogene status in patients with neuroblastoma. Our data suggest that PCNB could be optimized for complete genetic analysis by standardized protocols and real-time pathology assessment of specimen quality.

Citation Information
Richard E. Overman, Tanvi T. Kartal, Aaron J. Cunningham, Elizabeth A. Fialkowski, et al.. "Optimization of percutaneous biopsy for diagnosis and pretreatment risk assessment of neuroblastoma" Pediatric Blood and Cancer Vol. 67 Iss. 5 (2020)
Available at: http://works.bepress.com/andreana-butter/9/